This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

18 Jul 2011

Sanofi-Aventis and Regeneron Report Sarilumab Study Results

Sanofi-Aventis and Regeneron Pharmaceuticals Inc said their experimental drug Sarilumab showed signs of improvement in rheumatoid arthritis patients in a mid-stage trial.

Sanofi-Aventis and partner Regeneron Pharmaceuticals have reported clinical results from two Phase IIb studies of Sarilumab in rheumatoid arthritis and ankylosing spondylitis patients.


Sarilumab is a novel, high-affinity, subcutaneously administered, fully-human antibody that targets the interleukin-6 receptor.


The 306 patient, dose-ranging, multi-national, randomised, multi-arm, double-blind and placebo-controlled MOBILITY trial demonstrated that patients treated with Sarilumab in combination with methotrexate achieved improvement in signs and symptoms of rheumatoid arthritis at 12 weeks.


Sanofi-Aventis global research and development president Elias Zerhouni sa

Related News